AMD

Retina Then and Now: March Spotlight

As part of our 20th anniversary, Retina Today is digging into the archives to reflect on how much the profession has changed.

Robert L. Avery, MD

Optogenetics: Bringing Light to the Blind

A primer on the mechanism of action and what’s in the pipeline.

Vinit B. Mahajan, MD, PhD

Anti-VEGF and Beyond: Expanding Therapeutic Options for Wet AMD

A 2025 review of clinical trials evaluating novel therapies for wet AMD.

Matthew Elitt, MD, PhD; Pariyamon Thaprawat, BS; and Nita Valikodath, MD, MS

Trials and Innovations in Geographic Atrophy Therapy

Novel mechanisms of action and delivery methods hold promise for patients with dry AMD.

James M. Harris, MD, PhD, and Eleonora M. Lad, MD, PhD

A Series of Rare Events in Geographic Atrophy Therapy

These cases highlight screening and follow-up considerations with anti-complement therapy.

Tina Tang, MD, and Nauman Chaudhry, MD

Retina by the Numbers

Allen C. Ho, MD, and Robert L. Avery, MD

Beyond Complement: Emerging Therapeutics for Dry AMD

Targeting inflammation, mitochondrial health, and neuroprotection.

Aumer Shughoury, MD, and Thomas A. Ciulla, MD, MBA

Gene Therapy for AMD: What You Need to Know

Several candidates with varying mechanisms of action and delivery methods are in clinical trials.

Szilárd Kiss, MD, FASRS, and Peyman Razavi, MD

Imaging Biomarkers for GA Progression

Our study identified a set of OCT parameters that can predict a faster growth rate.

Maxwell S. Mayeda, MD, and Talisa E. de Carlo Forest, MD

Emerging (Durable) Therapies for Wet AMD

New approaches are helping us care for patients while reducing their treatment burden.

Jacob S. Heng, MD, PhD, and Adrienne W. Scott, MD

FDA Guidance: What it Means for AMD Trials

Industry leaders discuss the shifts in clinical trial designs and their recent interactions with the FDA.

Nadia K. Waheed, MD, MPH; Ramiro Ribeiro, MD, PhD; Victor Chong, MD, MBA, FARVO; Lanita Scott, MD; and David J. Tanzer, MD

Wet AMD Therapies in the Pipeline

A review of clinical trials investigating novel approaches to wet AMD in 2024.

Saumya M. Shah, MD, and Daniel Su, MD

Geographic Atrophy Therapies to Watch

An update on complement inhibitors, gene and cell therapies, and novel approaches.

Rebecca Hepp, MA, Editor-in-Chief

Using AI to Identify Exudative Macular Disease

A new tool for OCT interpretation was able to detect macular edema secondary to retinal pathology with high accuracy.

Claudia P. Acosta, MD; Maria Adelaida Piedrahita, MD; Juan Gonzalo Sanchez, MD; Juliana Muñoz-Ortiz, MD; Julián Martinez; José Zea; Laura Velasquez; Juliana Mesa; Sebastian Menges; and Carolina Sardi, MD, MS

Photobiomodulation: Innovation on the Horizon for Dry AMD

A novel, noninvasive therapeutic approach may stave off vision loss.

Richard B. Rosen, MD

Cataract Surgery Implications for AMD

Research has not provided a definitive answer as to the connection between these conditions.

Ali Erginay, MD

IOLs and AMD: The Current Landscape

Emerging technologies and surgical considerations can make lens selection a challenge. Here’s what you need to know.

Stephanie B. Engelhard, MD, and Daniel Su, MD

Managing Wet AMD: The Promise of TKIs

This novel approach may help to mitigate the treatment burden associated with wet AMD therapy.

Rahul Iyengar, MD; Douglas Matsunaga, MD; and David S. Boyer, MD

Integrating Next-Generation Wet AMD Therapies

Experts discuss when they consider a newer treatment option for patients with suboptimal responses.

Linnet Rodriguez, MD, and Allen C. Ho, MD

A Retina Renaissance

Allen C. Ho, MD, and Robert L. Avery, MD